Gastrointestinal Malignancies Research Advancements: Insights from Farshid Dayyani, MD - Synopsis below extracted from the video transcript.
Recent developments in the examination of malignancies that affect the digestive tract are discussed by oncologist and researcher Dr. Farshid Dayyani. Throughout his presentation, he touches on a broad variety of subjects, including immunotherapy, targeted therapies, and biomarkers, among others. The presentation is split into multiple slides, each of which includes commentary on the most recent advancements in this sector. Individuals who are currently employed in the medical industry, as well as other individuals who are interested in learning more about the several treatment options that are available for gastrointestinal cancer, can benefit from viewing this presentation.
Read The Full Transcript and Watch The Video Here
How will gastroesophageal malignancies (gastric cancer) evolve? Two fascinating goals may soon change practice. Is bevacizumab an IgG1 monoclonal antibody targeting FGFR2b? This IHC test for FGFR2b protein overexpression is used to treat GI tumors like gastric cancer with TKIs for FGFR2 translocations and fusions. Dr. Weinberg from UCLA presented the FIGHT phase 2 randomized study in 2 20 21. Over 80 patients were randomized one-to-one to FOLFOX with or without BEMA. The main objective for progression-free survival (PFS) was met, and BEMA improved overall valve. Nonetheless, that investigation taught us that target expression matters. FGFR2b expression increases the relative benefit of the monoclonal antibody. Hence, FGFR2b overexpression led to the FoRtitude investigations, which involve two first-line randomized phase 3 trials. Hence, only high-expressor patients should be prescreened. Two trials use FOLFOX NIVO and BEMA. UCI has one competition to reduce competition. UCI 21-193. New metastatic gastroesophageal adenocarcinoma patients should consider this trial. Also, the investigation enables one FOLFOX cycle with or without NIVO.
